Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: " Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report | JOURNAL OF MEDICAL Sr CASE REPORTS Case report Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia a case report Hadi Alphonse Goubran Open Access Address Professor of Medicine and Clinical Haematology Faculty of Medicine Cairo University 73 Maadi 1431 Cairo Egypt Email hadigoubran@gmail.com Published 29 April 2009 Received 24 November 2008 Journal of Medical Case Reports 2009 3 7112 doi 10.1186.1752-1947-3-7112 Accepted 29 January 2009 This article is available from http jmedicalcasereports.Com jmedicalcasereports article view 3 4 7112 2009 Goubran licensee Cases Network Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 3.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Due to high rates of response and durable remissions imatinib Glivec or Gleevec in the USA Novartis Pharma AG is the standard of care in patients with chronic myeloid leukemia. Recently a non-authorized product which claims comparability to imatinib has become available. Case presentation This report describes the loss of response in a 36-year-old male patient with chronic-phase chronic myeloid leukemia who had previously been in full hematologic and cytogenetic remission and partial molecular remission for three years under treatment with brand-name imatinib of 400 mg per day. Before the initiation of treatment with a copy product imatib CIPLA-India the patient had negative BCR-ABL status. Within three months of initiation of treatment with the copy product the patient s BCR-ABL status became positive with substantial decreases noted in white blood cell counts red blood cell counts and platelet counts. Conversion of the BCR-ABL status to negative and improvements in hematologic parameters were achieved when the brand .